摘要
艾乐替尼是第二代用于治疗间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌的ALK酪氨酸酶抑制药,它能克服克唑替尼耐药的多个靶点,临床试验中具有很好的安全性及耐受性,本文对艾乐替尼的作用机制、药动学、临床疗效、安全性、耐药机制进行详细介绍。
Alectinib is a second-generation ALK inhibitor for the treatment of ALK-positive non-small-cell lung cancer, which can overcome many crizotinib-resistant targets with good tolerability and safety in clinical trials. Its mechanism of action, pharmacokinefics, clinical efficacy, safety and mechanism of resistance were introduced in the paper.
出处
《中国药师》
CAS
2016年第11期2130-2133,共4页
China Pharmacist
关键词
艾乐替尼
作用机制
临床疗效
安全性
耐药机制
Alectinib
Mechanism of action
Clinical efficacy
Safety
Drug resistance
